Gene Therapy Milestones: Gilead’s Acquisition of Kite Pharma and FDA’s Novartis CAR-T Approval Signal an Advancing Gene Therapy Field; What Are Key Takeaways for Gene Therapy Companies?
By Nancy Bradish Myers, Anne McNickle and Jill Hartzler Warner In the past week, we’ve seen significant advances in the gene therapy world. Within the span of two days, Gilead announced it will acquire Kite Pharma, which has a CAR-T therapy under review at FDA, and FDA approved Novartis’ CAR-T therapy, Kymriah (tisagenlecleucel, for